Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis

J Neuroimmunol. 2007 Apr;185(1-2):123-9. doi: 10.1016/j.jneuroim.2006.12.014. Epub 2007 Feb 15.

Abstract

We investigated whether glatiramer acetate (GA) treatment may affect Th1 differentiation at various T-cell maturation stages. Specifically, we analyzed the effect of in vivo GA treatment on intracellular synthesis of IL-2 and TNF-alpha by naive, memory and effector CD4(+) and CD8(+) T cells by five-colour flow cytometry. Our data indicate that GA treatment downregulates/normalizes an accelerated Th1 differentiation of CD4(+) T cells in RRMS patients at all stages of T-cell maturation. Most notably, we conclude that, by altering naive, unprimed CD4(+) T cells, GA treatment appears to affect T-cell differentiation, at least in part, in an antigen-independent manner.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / drug effects*
  • Cell Differentiation / drug effects*
  • Cell Differentiation / immunology
  • Female
  • Flow Cytometry
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-2 / biosynthesis
  • Male
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Peptides / therapeutic use*
  • Th1 Cells
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / drug effects

Substances

  • Immunosuppressive Agents
  • Interleukin-2
  • Peptides
  • Tumor Necrosis Factor-alpha
  • Glatiramer Acetate